Trivant Custom Portfolio Group, LLC Viking Therapeutics, Inc. Transaction History
Trivant Custom Portfolio Group, LLC
- $174 Billion
- Q1 2025
A detailed history of Trivant Custom Portfolio Group, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Trivant Custom Portfolio Group, LLC holds 10 shares of VKTX stock, worth $288. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10Holding current value
$288% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
459Shares Held
65.7MCall Options Held
5.8MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$294 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$174 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$142 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$74.9 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$62.3 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.21B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...